Integra LifeSciences Stock Price, News & Analysis (NASDAQ:IART)

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Integra LifeSciences in the last twelve months. There are currently 3 sell ratings, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" IART shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IART, but not buy additional shares or sell existing shares.
View IART analyst ratings or view top-rated stocks.

9 analysts have issued 1 year price targets for Integra LifeSciences' stock. Their IART share price targets range from $37.00 to $60.00. On average, they predict the company's stock price to reach $46.00 in the next twelve months. This suggests a possible upside of 11.4% from the stock's current price.
View analysts price targets for IART or view top-rated stocks among Wall Street analysts.

Integra LifeSciences' stock was trading at $56.07 at the beginning of 2023. Since then, IART stock has decreased by 26.3% and is now trading at $41.31.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our IART earnings forecast.

Integra LifeSciences Holdings Co. (NASDAQ:IART) announced its quarterly earnings results on Wednesday, October, 25th. The life sciences company reported $0.76 EPS for the quarter, missing the consensus estimate of $0.78 by $0.02. The life sciences company earned $382.40 million during the quarter, compared to the consensus estimate of $387.22 million. Integra LifeSciences had a net margin of 6.54% and a trailing twelve-month return on equity of 15.28%. The company's revenue was down .7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.86 earnings per share.

ETFs with the largest weight of Integra LifeSciences (NASDAQ:IART) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Fidelity Digital Health ETF (FDHT), ROBO Global Healthcare Technology and Innovation ETF (HTEC), First Trust Health Care AlphaDEX Fund (FXH), SPDR S&P Health Care Equipment ETF (XHE), WisdomTree U.S. AI Enhanced Value Fund (AIVL) and Invesco Nasdaq Future Gen 200 ETF (QQQS).iShares U.S. Medical Devices ETF (IHI).

Shares of Integra LifeSciences split on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly issued shares were issued to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Integra LifeSciences issued an update on its fourth quarter earnings guidance on Wednesday, October, 25th. The company provided EPS guidance of $0.89-0.93 for the period, compared to the consensus EPS estimate of $0.92. The company issued revenue guidance of $397-403 million, compared to the consensus revenue estimate of $405.49 million.

173 employees have rated Integra LifeSciences Chief Executive Officer Peter J. Arduini on Glassdoor.com. Peter J. Arduini has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Integra LifeSciences investors own include Boeing (BA), NVIDIA (NVDA), AbbVie (ABBV), Adobe (ADBE), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Marvell Technology (MRVL), Alexion Pharmaceuticals (ALXN) and Abbott Laboratories (ABT).

Integra LifeSciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Clearbridge Investments LLC (3.51%), Victory Capital Management Inc. (1.87%), Deerfield Management Company L.P. Series C (1.44%), AQR Capital Management LLC (0.98%), Assenagon Asset Management S.A. (0.85%) and Bank of New York Mellon Corp (0.81%). Insiders that own company stock include Eric Schwartz, Glenn Coleman, Jeffrey Mosebrook, Lisa Evoli, Michael J Mcbreen, Raymond G Murphy, Stuart Essig, Tru St Partnership, LP and Witte Jan De.
View institutional ownership trends.

Shares of IART stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.